CASI Pharmaceuticals Appoints James Huang to Board of Directors

Core Insights - CASI Pharmaceuticals has appointed James Huang as an Independent Director, effective October 1, 2025, bringing over 35 years of biotech experience [1] Company Overview - CASI Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapies for organ transplant rejection and autoimmune diseases [1] Leadership Impact - The appointment of James Huang is expected to significantly enhance the development program of CID-103, an anti-CD38 monoclonal antibody [1]